NASDAQ: ONC
Beigene Ltd Stock

$223.50-5.37 (-2.35%)
Updated Feb 7, 2025
ONC Price
$223.50
Fair Value Price
N/A
Market Cap
$23.85B
52 Week Low
$126.97
52 Week High
$248.16
P/E
-349.22x
P/B
6.94x
P/S
7.17x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.32B
Earnings
-$860.46M
Gross Margin
83.7%
Operating Margin
-25.77%
Profit Margin
-25.9%
Debt to Equity
0.7
Operating Cash Flow
-$437M
Beta
0.85
Next Earnings
Feb 24, 2025
Ex-Dividend
N/A
Next Dividend
N/A

ONC Overview

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine ONC's potential to beat the market

Zen Rating Component Grades

N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
ONC
Ranked
Unranked of 556

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important ONC news, forecast changes, insider trades & much more!

ONC News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ONC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ONC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ONC is poor value based on its book value relative to its share price (6.94x), compared to the US Biotechnology industry average (4.94x)
P/B vs Industry Valuation
ONC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ONC due diligence checks available for Premium users.

Valuation

ONC price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-349.22x
Industry
-146.27x
Market
30.7x

ONC price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
6.94x
Industry
4.94x
ONC is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ONC's financial health

Profit margin

Revenue
$1.0B
Net Income
-$121.4M
Profit Margin
-12.1%
ONC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ONC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$5.8B
Liabilities
$2.4B
Debt to equity
0.7
ONC's short-term assets ($3.91B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ONC's short-term assets ($3.91B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ONC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ONC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$188.4M
Investing
-$133.9M
Financing
$12.7M
ONC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ONC vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
ONC$23.85B-2.35%-349.22x6.94x
BNTX$28.20B-1.94%-56.38x1.37x
RPRXB$18.69B+1.05%12.35x1.82x
UTHRB$15.52B-1.71%14.30x2.54x
SMMTC$14.83B-2.71%-10,055.00x33.86x

Beigene Stock FAQ

What is Beigene's quote symbol?

(NASDAQ: ONC) Beigene trades on the NASDAQ under the ticker symbol ONC. Beigene stock quotes can also be displayed as NASDAQ: ONC.

If you're new to stock investing, here's how to buy Beigene stock.

What is the 52 week high and low for Beigene (NASDAQ: ONC)?

(NASDAQ: ONC) Beigene's 52-week high was $248.16, and its 52-week low was $126.97. It is currently -9.94% from its 52-week high and 76.03% from its 52-week low.

How much is Beigene stock worth today?

(NASDAQ: ONC) Beigene currently has 1,386,034,320 outstanding shares. With Beigene stock trading at $223.50 per share, the total value of Beigene stock (market capitalization) is $23.85B.

Beigene stock was originally listed at a price of $28.32 in Feb 3, 2016. If you had invested in Beigene stock at $28.32, your return over the last 9 years would have been 689.19%, for an annualized return of 25.8% (not including any dividends or dividend reinvestments).

How much is Beigene's stock price per share?

(NASDAQ: ONC) Beigene stock price per share is $223.50 today (as of Feb 7, 2025).

What is Beigene's Market Cap?

(NASDAQ: ONC) Beigene's market cap is $23.85B, as of Feb 8, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Beigene's market cap is calculated by multiplying ONC's current stock price of $223.50 by ONC's total outstanding shares of 1,386,034,320.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.